MedWatch

Analyst: Upgraded ALK sales guidance could still be beaten

Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.

Photo: ALK / PR

Second-quarter sales developments were solid at ALK, and there is a chance that the firm will surpass its upgraded expectations, or at least land at the upper end of the scale, says Sydbank analyst Søren Løntoft Hansen.

”It is a strong report. ALK is doing better than expected on both the top and bottom lines,” he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs